These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. FDA's MedWatch Program Monitors Drug Safety, But It Depends on Nurses to Report Adverse Events. Miller D ONS Connect; 2015 Sep; 30(3):49. PubMed ID: 26449124 [No Abstract] [Full Text] [Related]
4. MedWatch. FDA's 'heads up' on medical product safety. Henkel J FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445 [No Abstract] [Full Text] [Related]
5. FDA's role in drug product recalls. Crawford SY Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194 [No Abstract] [Full Text] [Related]
6. Report slams US FDA's drug safety reform efforts. Bristol N Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202 [No Abstract] [Full Text] [Related]
7. Adverse drug and device reactions in the oral cavity: surveillance and reporting. Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840 [TBL] [Abstract][Full Text] [Related]
8. FDA's adverse-event surveillance needs improvement, advisers say. Traynor K Am J Health Syst Pharm; 2005 Jul; 62(13):1336, 1338, 1340. PubMed ID: 15972368 [No Abstract] [Full Text] [Related]
9. Food and Drug Administration update. The MedWatch program. White GG; Love L J Toxicol Clin Toxicol; 1998; 36(1-2):145-9. PubMed ID: 9541064 [No Abstract] [Full Text] [Related]
10. Adverse drug events and the Freedom of Information Act: an apple in Eden. Stang PE; Fox JL Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939 [TBL] [Abstract][Full Text] [Related]
11. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Szarfman A; Machado SG; O'Neill RT Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774 [TBL] [Abstract][Full Text] [Related]
12. MEDWatch: the new FDA medical products reporting program. Kessler DA Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452 [No Abstract] [Full Text] [Related]
13. Regulatory experts debate FDA's authority. Young D Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140 [No Abstract] [Full Text] [Related]
14. MedWatch: the FDA medical products reporting program. Rheinstein PH Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493 [No Abstract] [Full Text] [Related]
16. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment. Roller ST; Pippins RR; Ngai JW Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System. Muñoz MA; Dal Pan GJ Drug Saf; 2019 Oct; 42(10):1199-1201. PubMed ID: 31098918 [No Abstract] [Full Text] [Related]
18. MedWatch: the new medical products reporting program. Couig MP; Merkatz RB Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839 [No Abstract] [Full Text] [Related]
19. FDA's sentinel network: a monumental task. Young D Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189 [No Abstract] [Full Text] [Related]
20. FDA announces MedWatch: a new reporting program for health professionals. Hopkinson SE AANA J; 1993 Aug; 61(4):373-8. PubMed ID: 8379285 [No Abstract] [Full Text] [Related] [Next] [New Search]